Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Diagnostics

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
• Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced NSCLC, but predicting patient response remains challenging.
• Accurate biomarkers are needed to personalize ICI therapy and manage immune-related toxicities.

Purpose of the Study:

• To highlight the role of liquid biopsy in identifying predictive biomarkers for ICI therapy in NSCLC.
• To explore liquid biopsy's potential in monitoring treatment response and detecting resistance.
• To emphasize liquid biopsy's utility in guiding targeted therapy selection and adaptation.

Main Methods:

• Analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and immune cells in peripheral blood.
• Profiling of tumor mutational burden, neoantigen landscape, and immune activation states.
• Longitudinal monitoring through serial liquid biopsy sampling.

Main Results:

• Liquid biopsy provides insights into tumor-intrinsic and host-related factors influencing ICI response.
• Identifies predictive signatures for ICI efficacy and uncovers mechanisms of acquired resistance.
• Enables early detection of actionable mutations and resistance mechanisms for targeted therapies.

Conclusions:

• Liquid biopsy is a transformative, minimally invasive tool for real-time molecular and immunologic profiling in NSCLC.
• It facilitates personalized ICI therapy selection, response monitoring, and timely treatment adaptation.
• Liquid biopsy holds significant potential to improve patient outcomes in NSCLC by guiding therapy decisions.